Allery Treatment News

Bard Receives FDA Approval For The LifeStent(R) Vascular Stent

November 14, 2017

C. R. Bard, Inc., (NYSE: BCR) announced that it has received Pre-Market Approval (PMA) from the United States Food and Drug Administration to market the LifeStent® FlexStar and FlexStar XL Vascular Stent Systems. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries (SFA) and proximal popliteal arteries, and are marketed by the Bard Peripheral Vascular Division, located in Tempe, Arizona.

Two-year clinical data on the LifeStent® vascular stent demonstrated a freedom from target lesion revascularization rate of 78% vs. 42% (p